Your browser doesn't support javascript.
loading
Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines.
Liang, Chieh-Yu; Raju, Saravanan; Liu, Zhuoming; Li, Yuhao; Asthagiri Arunkumar, Guha; Case, James Brett; Scheaffer, Suzanne M; Zost, Seth J; Acreman, Cory M; Gagne, Matthew; Andrew, Shayne F; Carvalho Dos Anjos, Deborah Carolina; Foulds, Kathryn E; McLellan, Jason S; Crowe, James E; Douek, Daniel C; Whelan, Sean P J; Elbashir, Sayda M; Edwards, Darin K; Diamond, Michael S.
Affiliation
  • Liang CY; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
  • Raju S; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Liu Z; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
  • Li Y; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Asthagiri Arunkumar G; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Case JB; Moderna, Inc., Cambridge, MA, USA.
  • Scheaffer SM; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Zost SJ; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Acreman CM; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Gagne M; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Andrew SF; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Carvalho Dos Anjos DC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Foulds KE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • McLellan JS; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Crowe JE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Douek DC; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Whelan SPJ; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Elbashir SM; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Edwards DK; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Diamond MS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Nature ; 630(8018): 950-960, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38749479
ABSTRACT
Immune imprinting is a phenomenon in which prior antigenic experiences influence responses to subsequent infection or vaccination1,2. The effects of immune imprinting on serum antibody responses after boosting with variant-matched SARS-CoV-2 vaccines remain uncertain. Here we characterized the serum antibody responses after mRNA vaccine boosting of mice and human clinical trial participants. In mice, a single dose of a preclinical version of mRNA-1273 vaccine encoding Wuhan-1 spike protein minimally imprinted serum responses elicited by Omicron boosters, enabling generation of type-specific antibodies. However, imprinting was observed in mice receiving an Omicron booster after two priming doses of mRNA-1273, an effect that was mitigated by a second booster dose of Omicron vaccine. In both SARS-CoV-2-infected and uninfected humans who received two Omicron-matched boosters after two or more doses of the prototype mRNA-1273 vaccine, spike-binding and neutralizing serum antibodies cross-reacted with Omicron variants as well as more distantly related sarbecoviruses. Because serum neutralizing responses against Omicron strains and other sarbecoviruses were abrogated after pre-clearing with Wuhan-1 spike protein, antibodies induced by XBB.1.5 boosting in humans focus on conserved epitopes targeted by the antecedent mRNA-1273 primary series. Thus, the antibody response to Omicron-based boosters in humans is imprinted by immunizations with historical mRNA-1273 vaccines, but this outcome may be beneficial as it drives expansion of cross-neutralizing antibodies that inhibit infection of emerging SARS-CoV-2 variants and distantly related sarbecoviruses.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunization, Secondary / Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / MRNA Vaccines / Antibodies, Viral Limits: Adult / Animals / Female / Humans / Male Country/Region as subject: Asia Language: En Journal: Nature Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunization, Secondary / Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / MRNA Vaccines / Antibodies, Viral Limits: Adult / Animals / Female / Humans / Male Country/Region as subject: Asia Language: En Journal: Nature Year: 2024 Document type: Article Affiliation country: